August 9, 2016

Press Release
CompanyGreenPeptide Co., Ltd.

Representative

Kenichi Nagai, President & CEO(Code: 4594 TSE Mothers)

Inquiries

Teruhiko Sakai, Director/CFO(TEL.03-5840-7697)

Announcement of Joint Research and Development with Kanagawa Cancer Center
GreenPeptide wishes to announce that it has concluded a joint research agreement withKanagawa Prefectural Hospital Organization for research on the discovery and clinicalapplication of Neoantigens*1 (tumor antigens arising from somatic mutations in cancer cell)aiming at their clinical application as new cancer immunotherapy candidates.
(1) Research objectives
With the appearance of immune checkpoint inhibitors in recent years, genetic mutations
arising in cancer cells are now receiving attention as new cancer immunotherapy targets. Also,with the development of next generation gene sequencers*2, in the last 10 years, there havebeen dramatic advances in gene decoding technologies and it has become possible to morecomprehensively analyze antigens*3 used as markers when the immune systems of cancer
patients attack cancer cells.
Soon after the discovery of tumor antigens by Dr. Boon in 1991, from among several
hundred new antigen peptides that Kurume University comprehensively researched andidentified in the 1990s and 2000s, GreenPeptide has been conducting clinical studies on thosewith immune-enhancing capability as new cancer immunotherapy candidates both in Japan(ITK-1) and the USA (GRN-1201).
On the basis of this experience and technological innovations in recent years, GreenPeptide
will proceed with research aiming at the discovery and clinical application of Neoantigens(tumor antigens arising from somatic mutations in cancer cell), which have been receivingmuch attention as next generation cancer immunotherapy targets in recent years.
Dr. Tetsuro Sasada Director of Cancer Vaccine Center in Kanagawa Cancer Center, whowill jointly conduct the research with us, is currently moving forward with the research on
Neoantigens on the basis of his experience gained through participation in several basic1research and clinical research projects in cancer immunotherapy as well as his involvementin the clinical development of the immune checkpoint inhibitor, ipilimumab (anti-CTLA-4
antibody). GreenPeptide therefore expects robust collaboration in the joint research.
(2) Collaboration with research institute of Kanagawa Prefectural Hospital Organization
Our partner in the collaborative research will be the Cancer Immunotherapy R&D
department of Kangawa Cancer Center Research Institute (http://kcch.kanagawapho.jp/kccri/organization/menekiryoho.html), the research unit of one of the 5 prefectural
hospitals in Kanagawa Prefecture operated by the Kanagawa Prefectural HospitalAssociation.
The research institute has been in operation for 30 years since its founding and has muchknowledge of the cancer peptide vaccine therapies that GreenPeptide is developing as wellas other cancer immunotherapies. It also has a track record in the identification and evaluationof Neoantigens so we feel that the collaboration will be highly significant to our future
research and development activities.
(3) Details of research collaboration
Research project
Exploratory Research on New Cancer Immunotherapy
nameTargets
Objectives andDiscovery and evaluation of molecules with potential to benature of researchtargets for new immunotherapies against Neoantigens
Organizations
Kanagawa Cancer Center Research Instituteconducting research
GreenPeptide Co., Ltd.
Period of research
Date of concluding agreement to March 31, 2018(4) Effect on Company results
The effect of the conclusion of the present collaborative research agreement on thecompany’s results in the year to March 2017 will be minimal.
【Explanation of terms】*1
Neoantigen: A mutation antigen arising from somatic mutations in cancer cell, which
is only expressed on cancer cell (not expressed on normal cell). It has been reported thatSpecific Neoantigens in cancer cell have high potential for response of immune systemand that immunotherapy based on immune checkpoint inhibitors is readily effective
against cancers with numerous Neoantigens.
*2
Next Generation Sequencer (NGS)︓A general term applying to devices that decode
genetic sequences. Tremendous advances have been made in recent years, one of them
the achievement of high-speed decoding.
*3
Antigen: Antigen is a target molecule recognized and attacked by the immune system(cytotoxic T cells), such as a protein made by a cancer cell, or a fragment of one

2

(peptide). ITK-1 (Phase III clinical trial underway in Japan) and GRN-1201 (Phase I
clinical trial underway in USA) are both cancer peptide vaccines and consist of several
chemically synthesized peptides that are present in the body.
About GreenPeptide Co., Ltd.
GreenPeptide is a drug discovery venture company engaged in the research and developmentof cancer immunotherapies that make use of the body’s immune system to fight cancer. Thereare hopes that cancer immunotherapies will be the 4th therapy when surgery, radiotherapy andchemotherapy have failed.
Having 2 cancer peptide vaccines (ITK-1 for prostate cancer, GRN-1201 for malignant
melanoma) as mainstay products, GreenPeptide aims to contribute to innovation in cancer
therapy through the creation of novel cancer immunotherapies that disseminate a new drug
discovery concept originating in Japan worldwide.

3